- Coordinator
- Universiteit Antwerpen, Belgium
- Runs
- 1 September 2022 to 31 August 2026
- Status
- Running
- EU funding
- €2.3m
- Total cost
- —
- Partners
- 22 organisations in 9 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101073231
What the project is doing
In the project's own words, from its summary on CORDIS.
Europe has a high cancer burden: in 2020, 2.7 million EU citizens were diagnosed with the disease and 1.3 million lost their lives to it. This toll is expected to increase further, mainly because Europe's population is ageing: by 2035, cancer will be the leading cause of death in the EU. In 2021, the EC published its ‘Europe's Beating Cancer Plan’ (EBCP), calling for a big push in cancer research. Cancer diagnostics and therapeutics should rapidly become more effective and selective, patient-friendly and personalized.
All these goals are directly addressed by developing better tumor targeting strategies. Typically, they consist of equipping diagnostics and therapeutics with a vector unit. The vector unit binds to a protein that is overexpressed on cancer cells or in the Tumor Micro-Environment (TME), causing the diagnostic or therapeutic payload to accumulate in the tumor. Over the last decades, huge effort has gone in approaches that use antibodies as vectors, but return-on-investment has overall been rather poor.
Exciting, recent innovations rely on small molecule vectors that target TME proteases. Proteases are ideal candidates for tumor targeting: they are often strongly overexpressed in the TME and possess an active site that allows high-affinity anchoring of vectors. Members of this consortium have played a leading role in these developments. OncoProTools wants to force breakthroughs in cancer diagnosis and therapy by:1) Exploring innovative venues for protease targeting in CAR T cell therapy. 2) Discovering novel vectors that bind to other TME proteases: cathepsins S, B, L and granzyme B3) Personalize applications of protease targeting: deliver innovative diagnostics through deeper understanding of TME biology.
At the same time, OncoProTools will deliver a training program that truly captures the MSCA values, to 10 Doctoral Candidates. They will be provided with all capabilities to become leaders of tomorrow's R&I in Europe.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universiteit Antwerpen | Antwerpen | Belgium | Coordinator |
| Cancer Patients Europe | Bruxelles / Brussel | Belgium | Associatedpartner |
| European Cancer Patient Coalition | Bruxelles / Brussel | Belgium | Associatedpartner |
| Fox Biosystems NV | Diepenbeek | Belgium | Associatedpartner |
| HistoGeneX N.V. | Berchem | Belgium | Associatedpartner |
| Quintessence Consulting | Edegem | Belgium | Associatedpartner |
| Vixen Biosystems BV | Antwerpen | Belgium | Associatedpartner |
| Insel Gruppe AG | Bern | Switzerland | Associatedpartner |
| Universitaet Bern | Bern | Switzerland | Associatedpartner |
| Helmholtz-Zentrum Dresden-Rossendorf eV | Dresden | Germany | Participant |
| Johannes Gutenberg-Universitat Mainz | Mainz | Germany | Participant |
| SCV GmbH | Berlin | Germany | Associatedpartner |
| Technische Universitaet Dresden | Dresden | Germany | Associatedpartner |
| Kobenhavns Universitet | Kobenhavn | Denmark | Participant |
| Agencia Estatal Consejo Superior De Investigaciones Cientificas | Madrid | Spain | Participant |
| Universidad Autonoma De Madrid | Madrid | Spain | Associatedpartner |
| Cromed Kutato Es Szolgaltato Kozpontok Kft | Budapest | Hungary | Participant |
| Semmelweis Egyetem | Budapest | Hungary | Associatedpartner |
| Alma Mater Studiorum - Universita Di Bologna | Bologna | Italy | Associatedpartner |
| Cellply SRL | Bologna | Italy | Participant |
| Dehne Matthias | Amsterdam | Netherlands | Associatedpartner |
| Faculdade de Farmácia da Universidade de Lisboa | Lisboa | Portugal | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI